November 12, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051
Symbol: LUPIN

BSE Limited
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

We are pleased to enclose a Press Release titled "Lupin Announces European Launch of Biosimilar Ranibizumab".

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

AMIT
KUMAR
GUPTA



AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)

Encl.: a/a.

Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPCIN

Lupin Announces European Launch of Biosimilar Ranibizumab

Mumbai, India, November 12, 2026: Global pharma major Lupin Limited (Lupin) today announced that its commercial partner, Sandoz has launched Ranluspec™, Lupin's biosimilar Ranibizumab, across Europe, excluding Germany.

The launch follows the European Commission approval of Ranluspec™ in vial and pre-filled syringe presentations and marks an important step in expanding access to high-quality biologic treatment options for retinal diseases.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. The indications of Ranluspec™ encompass the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization.

Thierry Volle, President EMEA and Emerging Markets, Lupin, said, "The launch of Ranluspec in Europe advances Lupin's strategy of bringing high-quality biosimilars to more patients suffering from retinal and choroidal vascular diseases. Together with Sandoz, we will expand access to this important treatment across the region."

"The launch of Ranluspec reinforces our growing capabilities in biosimilars as it brings together our scientific expertise and manufacturing capabilities in biologics. It underscores our commitment to addressing unmet needs while supporting more sustainable healthcare systems," said **Dr. Cyrus Karkaria, President – Biotech Business, Lupin.**

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 6 research centers globally, along with a dedicated workforce of over 26,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries, please contact:

Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPCIN

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com